Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Holding(s) in Company

23 Jun 2020 11:38

RNS Number : 8096Q
Evgen Pharma PLC
23 June 2020
Β 

Β 

Β 

Β 

Β 

Β 

Β 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

Β 

Β 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Evgen Pharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

√

Β 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

Β 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

Β 

An event changing the breakdown of voting rights

Β 

Other (please specify):

change in percentage of voting rights arising upon a new issue of shares by the issuer

Β 

3. Full name of person(s) subject to thenotification obligation: iii

Enterprise Ventures Limited

4. Full name of shareholder(s)Β (if different from 3.):iv

RisingStars Growth Fund II LP

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

19th June 2020

6. Date on which issuer notified:

23rd June 2020

7. Threshold(s) that is/are crossed orreached: vi, vii

6%/5%/4%

Β Β Β Β Β Β 
Β 

Β 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights

Direct

Direct xi

Indirecti

Direct

Indirect

GB00BSVYN304

8,799,485

8,799,485

4,419,268

4,419,268

Nil

3.33

Nil

Β 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

None

Β 

Β 

Β 

Β 

Β 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

Β 

% of voting rights xix, xx

Β 

None

Β 

Β 

Β 

Β 

Β 

Nominal

Delta

Β 

Β 

Β 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

4,419,268

3.33%

Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β Β 
Β 

Β 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

Β 

Β 

Β 

Proxy Voting:

10. Name of the proxy holder:

Β 

11. Number of voting rights proxy holder will ceaseto hold:

Β 

12. Date on which proxy holder will cease to holdvoting rights:

Β 

Β 

13. Additional information:

Β 

14. Contact name:

Enterprise Ventures Limited

15. Contact telephone number:

Β 01772 270 570

Β Β Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
HOLFZGZVGFFGGZM
Date   Source Headline
25th Apr 20243:46 pmRNSChange of Name
22nd Apr 202410:11 amRNSHolding(s) in Company
11th Apr 20243:04 pmRNSHolding(s) in Company
9th Apr 20247:00 amRNSHolding(s) in Company
8th Apr 20244:03 pmRNSHolding(s) in Company
5th Apr 20243:39 pmRNSDirector/PDMR Shareholding
5th Apr 20242:40 pmRNSHolding(s) in Company
4th Apr 20241:59 pmRNSResult of General Meeting
4th Apr 20247:00 amRNSResult of Retail Offer
19th Mar 20245:03 pmRNSRetail Offer
19th Mar 20245:00 pmRNSAcquisition, Fundraising and Change of Name
27th Feb 20247:00 amRNSSFX-01 positive update in bowel cancer models
19th Feb 202411:22 amRNSPositive update on SFX-01 in vitro GBM studies
9th Feb 202411:01 amRNSNotice of Dispute lodged with Stalicla SA
16th Jan 20243:07 pmRNSSeries B Fund Raise by partner, Stalicla SA
29th Dec 202311:29 amRNSHolding(s) in Company
22nd Dec 20237:00 amRNSDirectorate Changes
13th Nov 20237:00 amRNSUpcoming conferences
31st Oct 20237:00 amRNSHalf-year Report
26th Oct 20237:00 amRNSErasmus Medical Center begins glioblastoma studies
19th Oct 20232:26 pmRNSAuthored Article Publication
5th Sep 20237:00 amRNSDirectorate Changes
15th Aug 20237:00 amRNSFinal Report from Phase 1b PK/PD study
3rd Aug 202312:38 pmRNSRule 17 Disclosure
2nd Aug 20237:00 amRNSReturn of rights to Sulforadex from Juvenescence
21st Jul 202312:02 pmRNSResult of AGM
27th Jun 20237:00 amRNSSFX-01 radiosensitisation effect confirmed in-vivo
20th Jun 20231:59 pmRNSNotice of AGM & Posting of Annual Report
19th Jun 20237:00 amRNSGrant Success for Glioblastoma studies
7th Jun 20237:00 amRNSFinal Results
26th May 202311:00 amRNSNotice of Results
22nd Mar 20237:00 amRNSPreliminary results from Phase 1b study
16th Mar 20232:00 pmRNSPrice Monitoring Extension
16th Mar 202311:05 amRNSSecond Price Monitoring Extn
16th Mar 202311:00 amRNSPrice Monitoring Extension
16th Mar 20237:00 amRNSFurther evidence of radiosensitisation by SFX-01
13th Mar 20237:00 amRNSNo exposure to Silicon Valley Bank
25th Jan 20237:00 amRNSClinical trial update
14th Dec 20225:08 pmRNSGrant of Options - Director/PDMR Shareholding
12th Dec 202211:54 amEQSEvgen Pharma 'cash runway in pretty good shape'
8th Dec 20227:00 amRNSHalf-year Report
2nd Dec 20227:00 amRNSNotice of Half Year Results
30th Nov 20222:06 pmRNSSecond Price Monitoring Extn
30th Nov 20222:00 pmRNSPrice Monitoring Extension
16th Nov 20227:00 amRNSStudy started of new SFX-01 tablet formulation
21st Oct 202211:05 amRNSSecond Price Monitoring Extn
21st Oct 202211:00 amRNSPrice Monitoring Extension
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 20227:00 amRNSClinical trial update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.